Literature DB >> 8739889

Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone.

J M Martins1, A J Kastin, W A Banks.   

Abstract

Corticotropin-releasing hormone (CRH) is produced and acts both within the central nervous system and at several peripheral sites. However, it is not known whether CRH is able to cross the blood-brain barrier (BBB) in either direction, or whether the central and peripheral compartments are independent. We studied the transport across the BBB of both human/rat CRH (hCRH) and ovine CRH (oCRH) using the native peptides labeled with 125I at the histidine residue, thereby avoiding the use of other synthetic modifications. No apparent transport of either hCRH or oCRH into the brain from blood was found, as measured by multiple-time regression analysis after intravenous injection of the labeled peptides. There were no significant differences between the two forms of the CRH peptide. However, both hCRH and oCRH were rapidly transported out of the brain after intracerebroventricular injection, with half-time (t1/2) disappearances of 11.1 (hCRH) and 15.1 min (oCRH); the transport rate was significantly different for the human and ovine forms. The transport of hCRH could be specifically inhibited by 5 nmol of unlabeled hCRH (t1/2 = 17.7 min) but not by the same dose of the synthetic analog alpha CRH12-41. The process could also be inhibited by pretreatment with aluminum chloride (t1/2 = 18.8 min). An indirect influence of the endogenous opiate modulating peptide Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2, 5 nmol) was apparent by a change in the initial distribution within the brain. In conclusion, there is a specific unidirectional brain to blood transport system for CRH. This transport system in the mouse has a greater affinity for the human/rat than for the ovine form of the peptide, is inhibited by hCRH itself, and can be disrupted by pretreatment with aluminum. By facilitating the rapid clearance of central CRH, this transport system could be involved in the regulation of central CRH levels and could allow central CRH to reach the general circulation and act at peripheral sites.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739889     DOI: 10.1159/000126974

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  20 in total

1.  Permeability of porcine blood brain barrier to somatostatin analogues.

Authors:  Gert Fricker; Stephanie Nobmann; David S Miller
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

3.  Distribution and chemical coding of corticotropin-releasing factor-immunoreactive neurons in the guinea pig enteric nervous system.

Authors:  Sumei Liu; Na Gao; Hong-Zhen Hu; Xiyu Wang; Guo-Du Wang; Xiucai Fang; Xiang Gao; Yun Xia; Jackie D Wood
Journal:  J Comp Neurol       Date:  2006-01-01       Impact factor: 3.215

4.  Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system.

Authors:  J C Bittencourt; P E Sawchenko
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

5.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

6.  Alpha-melanocyte-stimulating hormone attenuates behavioral effects of corticotropin-releasing factor in isolated guinea pig pups.

Authors:  Patricia A Schiml-Webb; Emily Miller; Terrence Deak; Michael B Hennessy
Journal:  Dev Psychobiol       Date:  2009-07       Impact factor: 3.038

7.  Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome.

Authors:  Y Sagami; Y Shimada; J Tayama; T Nomura; M Satake; Y Endo; T Shoji; K Karahashi; M Hongo; S Fukudo
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 8.  Urocortin and the brain.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Prog Neurobiol       Date:  2007-11-07       Impact factor: 11.685

9.  Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.

Authors:  Muriel Larauche; Guillaume Gourcerol; Lixin Wang; Karina Pambukchian; Stefan Brunnhuber; David W Adelson; Jean Rivier; Mulugeta Million; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-30       Impact factor: 4.052

10.  Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome.

Authors:  S Fukudo; T Nomura; M Hongo
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.